Teduglutide: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
DMC (Denmark), G-BA (Germany) and NYE METODER (Norway), among others, recommended or restricted teduglutide, while AOTMIT (Poland) and ZIN (Netherlands) did not recommend it.
Assessment has run over 10.8 years, from 3 Dec 2014 at HAS (France) to 21 Sep 2025 at NYE METODER (Norway).
PBAC (Australia) changed its position: not recommended in 2017, recommended by 2021, after a resubmission.
No assessment is on file from TLV (Sweden) and CIPM (Spain), each among the eight highest-volume agencies here.
Not every gap is a refusal: for teduglutide, 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 8 of 25 records date from 2023 or later.
5 distinct indication wordings are recorded for teduglutide by the agencies that label one in English (AWMSG, NICE, PBAC and SMC).
4 of these 25 records carry a year of decision but no day, so any interval quoted here is approximate to within a year.
HAS (France) was first to assess teduglutide, on 3 Dec 2014; NYE METODER (Norway) did not open a file until 21 Sep 2025 — an unusually long tail of 10.8 years between the earliest and latest system to look at it.
The record arrives in waves: 7 separate years each carry two or more decisions, spread across 11 years in total.
5 of the 12 agencies here assessed teduglutide more than once, HAS (France) most often at 8 entries — repeat review is the norm for this molecule rather than the exception.
teduglutide has been through 12 of the 18 agencies in this archive — among the most widely assessed molecules on file.
The full ledger for teduglutide reads 14 recommended, 5 not recommended, 2 restricted and 1 terminated, with 3 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| NYE METODER (Norway) | 21 Sep 2025 | Behandling av kort tarm-syndrom hos pasienter fra 4 måneders korrigert alder (corrected gestational age) og eldre. | introduced | source |
| AOTMIT (Poland) | 10 Jan 2025 | programu lekowego „Leczenie chorych z zespołem krótkiego jelita (ICD -10: K91.2) | not recommended | source |
| DMC (Denmark) | 25 Sep 2024 | Behandling af voksne og børn (> 1 år) med korttarmssyndrom. Patienterne skal være stabile efter en periode med intestina… | Anbefalet | source |
| HAS (France) | 24 Apr 2024 | Re-assessment of SMR and ASMR | SMR substantial · ASMR IV | source |
| PHARMAC (New Zealand) | 11 Aug 2023 | Short bowel syndrome intestinal failure for children | PTAC advice: High | source |
20 further decisions for teduglutide, across 10 agencies, are not shown here. They link to 11 further source documents.
Related molecules
- sapropterin — same ATC class A16A — Other alimentary tract and metabolism
- miglustat — same ATC class A16A — Other alimentary tract and metabolism
- migalastat — same ATC class A16A — Other alimentary tract and metabolism
- cerliponase alfa — same ATC class A16A — Other alimentary tract and metabolism
- givosiran — same ATC class A16A — Other alimentary tract and metabolism
- velmanase alfa — same ATC class A16A — Other alimentary tract and metabolism
Coverage: 25 decisions for teduglutide from 12 agencies, 2014 to 2025. Data to 7 Sep 2026. ATC class A16A — Other alimentary tract and metabolism. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.